Agonist Antibodies: Why CD40, OX40 & 4-1BB Need FcγR Crosslinking
An agonist antibody does not activate its receptor. It gets held still by something else, and the receptors underneath cluster because they are crowded. The TNF receptor superfamily signals by proximity: a natural ligand such as CD40L or 4-1BBL arrives as a membrane-anchored trimer and is clustered further into higher-order arrays by the presenting cell. A soluble, bivalent IgG cannot reproduce that on its own however tightly it binds \u2014 so the clustering is supplied by a third party, an Fc\u03b3 receptor on a passing myeloid or B cell, which acts as a scaffold rather than as a signal. The counter-intuitive consequence is that the inhibitory receptor Fc\u03b3RIIb is the best crosslinker of the set, because it holds antibodies densely and signals into nothing. Change the Fc\u03b3R environment and the same molecule becomes inert in one tissue and hepatotoxic in another. Click any protein for the matching Assay Genie In Vivo antibody, biosimilar or ELISA kit.
Proximity, not occupancy. TNF receptor superfamily members have no intrinsic enzymatic activity and no conformational switch to throw. They signal when enough of them are brought close enough together for TRAF2 and TRAF5 to be recruited to adjacent tails, which is why the natural ligands are trimers presented on a membrane and further clustered into arrays by the presenting cell. 4-1BBL makes the point most bluntly: it is inert in soluble form and active only when membrane-bound. A bivalent IgG can bridge two receptors, and two is not enough. Affinity maturation does not help, because the limiting quantity is geometry.
So the agonism is borrowed. What supplies the missing clustering in vivo is an Fc\u03b3 receptor on a neighbouring cell, holding many antibody molecules in a dense lattice. The surprise is which receptor does it best: Fc\u03b3RIIb, the inhibitory one, is the superior crosslinker precisely because it is a passive scaffold that signals into nothing. Fc\u03b3RIIa and Fc\u03b3RIIIa crosslink too, but they also activate the myeloid cell doing the holding \u2014 which is where the cytokine release comes from \u2014 and Fc\u03b3RIIIa triggers ADCC, so an IgG1 agonist can delete the cells it was meant to stimulate. On a Treg-rich target such as GITR that deletion may be the therapeutic mechanism; on an effector T cell it is the opposite of one. This is why isotype and Fc engineering change an agonist's behaviour more than its variable region does, and why potency measured on an Fc\u03b3R-free cell line predicts almost nothing about what happens in tissue.
Read the slow arm, not the fast one. Clustering feeds both NF-\u03baB arms, but only one of them reports on it. The canonical arm through IKK\u03b2 to RelA is fast, transient and shared with every inflammatory receptor in the cell, including TLR4 \u2014 which is exactly why an agonist antibody carrying endotoxin produces a convincing-looking result for entirely the wrong reason. The non-canonical arm is different in kind: TRAF3 and cIAP1 keep NIK continuously degraded, clustering destroys that complex, and NIK accumulates by the cessation of destruction rather than by any positive signal. Processing of p100 to p52 then takes hours and requires the lattice to hold throughout. That slowness is the assay: it is the step a non-crosslinked antibody cannot fake.
The In Vivo tie-in, and an unusually decisive one. 14 of the 38 nodes are blockable with functional-grade antibodies, and one pair settles the central question outright: oxelumab (anti-OX40L) is stocked both as a standard In Vivo antibody and as an Fc-reduced variant of the same clone. Same epitope, same affinity, Fc\u03b3R engagement removed. Activity that survives the swap was intrinsic; activity that disappears was borrowed from the bystander cell. The in vivo counterpart is the mouse CD16/CD32 blocker, which removes the scaffold in the animal. The agonist receptors themselves \u2014 CD40 (clone FGK45), OX40 (OX-86), 4-1BB, ICOS and CD70 \u2014 are all covered, and the CD40 antibody is stocked ultra-low endotoxin, which on this pathway is not a refinement but a requirement: LPS licenses dendritic cells through TLR4 and produces very nearly the same read-out. Stated plainly, what is not blockable here: the Fc\u03b3 receptors themselves, every TRAF, NIK, both NF-\u03baB subunits, IL-12, IL-6, Bcl-xL and survivin. GITR and CD27 are served by the ragifilimab and varlilumab biosimilars rather than by the functional-grade range, and carry no In Vivo dot for that reason. T-cell co-stimulation and the TNF receptor superfamily each have their own dedicated map in this library; this one deliberately does not redraw either, because its subject is not what these receptors do but why an antibody against them only works when something else is holding it. For research use only; not for use in diagnostic or therapeutic procedures.
Every protein node links to a product — ELISA kit, In Vivo antibody or research antibody.